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ABSTRACT
Dnmt1 is frequently overexpressed in cancers,
which contributes significantly to cancer-
associated epigenetic silencing of tumor suppres-
sor genes. However, the mechanism of Dnmt1
overexpression remains elusive. Herein, we eluci-
date a pathway through which nuclear receptor
SHP inhibits zinc-dependent induction of Dnmt1
by antagonizing metal-responsive transcription
factor-1 (MTF-1). Zinc treatment induces Dnmt1
transcription by increasing the occupancy of
MTF-1 on the Dnmt1 promoter while decreasing
SHP expression. SHP in turn represses MTF-1 ex-
pression and abolishes zinc-mediated changes in
the chromatin configuration of the Dnmt1 promoter.
Dnmt1 expression is increased in SHP-knockout
(sko) mice but decreased in SHP-transgenic (stg)
mice. In human hepatocellular carcinoma (HCC),
increasedDNMT1expressionisnegativelycorrelated
with SHP levels. Our study provides a molecular
explanation for increased Dnmt1 expression in
HCC and highlights SHP as a potential therapeutic
target.
INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the most
common malignancies in the world (1). HCCs are genet-
ically heterogeneous tumors that commonly emerge in the
presence of cirrhosis, that is often caused by viral hepatitis
or other chronic liver diseases (2). Recent insights into the
biology of HCC suggest that certain molecular alterations
promote hepatocyte proliferation and survival (3). HCC is
frequently advanced when detected and the 5-year survival
rate is generally <5%. There is a major need for a better
understanding of the molecular and cellular mechanisms
leading to HCC. Addressing this need is likely to improve
the early diagnosis and treatment of HCC.
Small heterodimer partner (SHP, NROB2) is a unique
member of the nuclear receptor superfamily (4) that func-
tions as a transcriptional repressor of genes critical to
metabolic diseases (5–16). We recently observed hepato-
cyte hyperproliferation and spontaneous hepatoma for-
mation in SHP-deﬁcient mice (17). On the other hand,
over-expression of SHP in SHP-transgenic mice-induced
hepatocyte apoptosis which was attributed to its unex-
pected role in mitochondria function (18). In addition,
diminished SHP expression by promoter hypermethyla-
tion occurred in human HCC specimens (19). An associ-
ation of SHP expression with HCC patient survival was
recently established (20), indicating that SHP may serve as
a good prognostic factor for liver cancer. These studies
suggest a role for SHP in hepatocarcinogenesis by
regulating cellular growth and apoptosis signaling.
Tumor suppressor gene silencing by promoter
hypermethylation is mainly controlled by three DNA
methyltransferases (Dnmt1, Dnmt3a and Dnmt3b) (21).
Dnmt1 is a critical gene to maintain CpG methylation
and aberrant gene silencing in human cancer cells (22).
Dnmt is frequently over-expressed in human cancers
(23). Interestingly, a lack of correlation between Dnmt
expression and DNA methylation status for several
tumor suppressor genes has been reported in HCC (24).
This suggests that other mechanisms and tumor suppres-
sor genes may be involved in hepatocarcinogenesis. Thus
far, several transcription factors have been identiﬁed to
regulate the expression of Dnmts, including sp1/sp3,
E2F and STAT3 (25–28). The expression of Dnmt1 is
also regulated via estrogen-related receptor gamma
(ERRg) and SHP crosstalk (29). Despite these studies,
the mechanism of Dnmt overexpression in cancers
remains elusive.
In this report, we showed that SHP is a transcriptional
repressor of the Dnmt1 expression via crosstalk with
metal-responsive transcription factor-1 (MTF-1) through
a zinc dependent mechanism. We revealed a feed forward
cross-inhibition between SHP and MTF-1 in ﬁne tuning
the expression of Dnmt1 via zinc. The diminished SHP
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provide a molecular basis which, in part, explains the
increased Dnmt1 expression in HCC.
MATERIALS AND METHODS
Cell lines, animals and human HCC specimens
Human cervix adenocarcinoma cells (Hela, ATCC
CCL-2), human hepatoma cells (Huh7, Health Science
Research Resources Bank JCRB0403; HepG2, ATCC
HB-8065), human fetal kidney cell line (HEK293, ATCC
CRL-1573), murine normal liver epithelial cell line
(Nmuli, ATCC CRL1638), mouse hepatoma cell line
Hepa-1 (ATCC CRL-1830), mouse embryonic ﬁbroblast
(MEF) cells prepared from wild-type (MTF-1
+/+) and
MTF-1 knockout (MTF-1
 / ) mice were maintained in
Dulbecco’s-modiﬁed Eagle’s medium (DMEM) with
100U of penicillin G-streptomycin sulfate/ml and 10%
heat-inactivated fetal bovine serum (FBS). The stably
re-expressed Flag-MTF-1 cells (designated as M42) were
described previously (30) and were maintained in DMEM
supplemented with 10% FBS and 200mg/ml hygromycin
B. SHP
+/+ [wild-type (wt)], SHP
 /  (sko), SHP
nontransgenic control (nc) and hepatocyte-speciﬁc SHP
transgenic (stg) mice were described previously (18).
Wild-type and sko were maintained on a pure C57BL/6
background and nc and stg were generated with a mixed
C57BL6/129sv hybrid background. Protocols for animal
use were approved by the Institutional Animal Care and
use Committee at the University of Utah. HCC specimens
were obtained through the Liver Tissue Cell Distribution
Service (LTCDS) (Minneapolis, MN, USA).
Plasmids, siRNA, adenovirus and antibodies
The mouse Dnmt1 (Gene ID: 13433) promoter luciferase
construct (Dnmt1Luc), mouse SHP (Gene ID: 23957)
promoter luciferase construct (SHPLuc), Flag-MTF1
and Flag-SHP were described previously (29–31). Mouse
SHP and non-speciﬁc small interfering RNAs (siRNAs)
were purchased from Ambion. Both the green ﬂuorescent
protein (GFP) control adenoviruses and the GFP–SHP
adenoviruses were described previously (18). The follow-
ing antibodies were used for chromatin immunopre-
cipitation (ChIP) and western blots (WBs): M-280 sheep
anti-rabbit or mouse IgG Dynabeads (Invitrogen Dynal
As), rabbit normal IgG (Sigma, R-2004) and antibodies
against Flag (Sigma, F-7425), b-actin (Sigma, A-1978),
Dnmt1 (Cell signaling, #5032), histone H3 acetyl
antibody (H3Ac) (Millipore, #06-599), histone H4 acetyl
antibody (H4Ac) (Millipore, #06-866), histone H3
dimethyl Lys4 antibody (H3K4Me2) (Millipore,
#07-030) and histone H3 dimethyl Lys9 antibody
(H3K9Me2) (Millipore, #17-648).
DNA methyltransferase activity assay
The DNA methyltransferase activity was assessed using
the EpiQuik
TM DNA methyltransferase activity/inhibition
assay kit (Epigentek, Brooklyn, NY, USA). Brieﬂy, 12mg
of nuclear extracts or 0–2.5 units of puriﬁed Dnmt
enzymes was incubated with 1.6mM of adomet for
60min at 37 C followed by the incubation with 1mg/ml
of capture antibody for 60min at room temperature. Then
each well was washed with wash buffer for four times and
incubated with 0.2mg/ml of detection antibody at room
temperature for 30min. Developing solution was added
and incubated for 2–10min away from light. Then reac-
tions were stopped and read at 450nm using a microplate
spectrophotometer (Benchmark plus, Bio-Rad).
Dnmt1 amount assay
The Dnmt1 amount was assessed using the epiquik
TM
Dnmt1 assay kit. Brieﬂy, 12mg of nuclear extracts or
0–10ng of puriﬁed Dnmt1 protein was incubated for
60min at 37 C followed by the incubation with 1mg/ml
of afﬁnity antibody for 60min at room temperature. Then
each well was washed four times and incubated with
0.2mg/ml of detection antibody at room temperature for
30min. Developing solution was added and incubated for
2–10min away from light. Then reactions were stopped
and read at 450nm using a microplate spectrophotometer
(Benchmark plus, Bio-Rad).
RT-PCR and real-time qPCR analysis
The method can be found in our recent publications
(18,32). In brief, qPCR was performed with total RNA
using the SYBR Green PCR master mix (Applied
Biosystems). The melting-curve data were collected to
check PCR speciﬁcity. Each cDNA sample was run as
triplicates, and the corresponding no-reverse transcriptase
(RT) mRNA sample was included as a negative control.
The amount of PCR products was measured by threshold
cycle (Ct) values and the relative ratio of speciﬁc genes
to HPRT1 for each sample was then calculated. The
sequences for the primers are available upon request.
Promoter activity assays
Detailed methods can be found in our recent publications
(18,33–36). In brief, Hela, MEF or HEK293 cells were
transfected with the plasmids as indicated in the ﬁgure
legends. Empty vector DNA was added as needed so
that the same amounts of expression vector DNA were
present in each transfection. Transfection was carried
out using Lipofectamine 2000 (Invitrogen). Luciferase
activities were measured and normalized against renilla
activities (Promega). Consistent results were observed in
three independent triplicate transfection assays.
ChIP assay
Detailed methods can be found in our recent publica-
tions (18,29,33–36). M42 cells were transfected with
the plasmids and chromatin crosslinked, and immunopre-
cipitations were performed with speciﬁc antibodies
as indicated in the ﬁgure legends, with rabbit normal
IgG as negative control (Upstate). Ethanol-extracted
DNA was used as the template to amplify the Dnmt1
promoter or SHP promoter. The sequences for
the primers are as follows: Dnmt1 promoter P1 forward
50-TGTGAGTGCAATGCCCATAGA-30 and reverse
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P1 forward 50-GACCTTGGTGCCCTGGTACA-30
and reverse 50-ATGCATACACGCTGACCCTG-30. The
control region from  1143nt to  950nt in the Dnmt1
promoter (forward 50-TGGCAGAAGTGGTTCCTG
G-30 and reverse 50-AAAGGCCTCCCGTCTAACCC-30)
and  1536nt to  1343nt in SHP promoter (forward 50-T
CTCTGCAGGGCTTTGCTCT-30 and reverse 50-TTCC
AGCCAGGGTTTCTCTG-30) are served as negative
controls, respectively.
WBs in cells and liver tissues
Detailed methods can be found in our recent publication
(37). Hepa-1 cells were transfected with Flag-SHP
plasmids and cultured for 36h. For Zn treatment, MEF
cells were incubated for up to 6h in medium containing
ZnSO4 (100mM). For WBs using mouse livers, 100mg of
liver fragments from 2-, 13- and 20-month-old SHP
 / 
mice or their respective controls were homogenized in
lysis buffer and subjected to WBs.
Statistical analysis
Data are expressed as the mean±SD. Statistical analyses
were carried out using Student’s unpaired t-test; P<0.01
was considered statistically signiﬁcant.
RESULTS
SHP-deﬁciency results in increased hepatic Dnmt1
expression
qPCR analysis of mRNA of three individual mice per
genotype revealed a moderate, although statistically insig-
niﬁcant, up-regulation of hepatic Dnmt1 mRNA in
2-month-old SHP
 /  (sko) mice relative to wt mice
(Figure 1A) and a signiﬁcant down-regulation of Dnmt1
mRNA in hepatocyte SHP-transgenic (stg) mice relative
to non-transgenic (nc) mice (Figure 1B). The levels of
Dnmt1 protein (Figure 1C) and Dnmt enzymatic activity
(Figure 1D) corresponded to the changes of Dnmt1
mRNA in sko and stg mice, i.e. increased in sko mice
and decreased in stg mice. In addition, the Dnmt1
protein was increased in the liver of 2-, 13- and
20-month-old sko mice as determined by WB (Figure 1E).
SHP inhibits Dnmt1 mRNA in mouse hepatocyte cell lines
Mouse hepatoma Hepa-1 cells lack SHP (17) but have
high levels of Dnmt1 whereas the mouse normal hepato-
cyte Nmuli cells have higher levels of SHP but low levels
of Dnmt1. Over-expression of SHP dose-dependently
decreased Dnmt1 mRNA in Hepa-1 cells (Figure 1F). In
contrast, knockdown of SHP in Nmuli cells with siRNA
against SHP led to the induction of Dnmt1 mRNA
Figure 1. SHP inhibition of Dnmt1 expression. (A and B) qPCR analysis of SHP and Dnmt1 mRNAs in the liver of wt and SHP
 /  (sko),
non-transgene (nc) and hepatocyte speciﬁc SHP transgenic (stg) mice (n=3 per genotype). (C and D) The levels of Dnmt1 protein (pt) and
enzymatic activity (act.) in the liver of wt and sko, nc and stg mice. (E) WB of Dnmt1 protein in wt and sko mice. (F) qPCR analysis of SHP
and Dnmt1 mRNA in Hepa-1 cells over-expressing SHP from an expression plasmid. (G) qPCR analysis of SHP and Dnmt1 mRNA in Nmuli cells
with SHP knockdown using an oligoSHP-siRNA (oligoRNAi). Statistical results represent mean±SD of triplicate assays (*P<0.01).
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is negatively regulated by SHP.
The expression of MTF-1 is repressed by SHP
MTF-1 is a transcription factor that activates the tran-
scription of metallothionein genes in response to heavy
metal load and other stresses such as hypoxia and oxida-
tive stress (38,39).
Examination of the correlation between SHP, MTF-1
and Dnmt1expression in vitro in Nmuli and Hepa-1 cell
cultures revealed an inverse relationship between SHP and
MTF-1/Dnmt1 (Figure 2A, left). Similarly, MTF-1 and
Dnmt1 are expressed in NIH3T3 cells in which SHP is
barely detectable and their expression was repressed
when the cells were transfected with a SHP expression
plasmid (Figure 2A, right). An inverse expression correl-
ation between SHP and MTF-1 was also observed in vivo
in mouse liver, in which MTF-1 mRNA was up-regulated
in sko versus wt mice but down-regulated in stg versus
nc mice at both 2 and 12 months of age (Figure 2B).
The decreased MTF-1 mRNA in 12-month-old wt mice
relative to 2-month-old mice was in agreement with the
higher SHP level in the older mice (data not shown). The
expression of MTF-1 target genes MTI and MTII was
strongly induced by zinc in sko as compared to the wt
mice (Figure 2C), conﬁrming the activation of MTF-1 in
sko mice.
The above observations suggest that SHP may inhibit
the expression of MTF-1. Indeed, over-expression of SHP
in Hepa-1 cells dose-dependently inhibited MTF-1 at both
the mRNA (Figure 2D) and protein (Figure 2E) levels.
Zinc decreases SHP expression through MTF-1
MTF-1 can be activated in response to heavy metal
exposure (39,40). In Nmuli cells when MTF-1 was
activated by treatment with exogenous zinc (Zn), a
marked reduction in SHP mRNA was observed (Figure
3A, left). Zinc treatment also decreased SHP mRNA in
MTF-1
+/+ MEF cells (Figure 3A, right). Interestingly, the
basal SHP mRNA was decreased in MTF-1
 /  MEFs
which was up-regulated by zinc. This suggests that, in
the absence of MTF-1, zinc may regulate SHP through
alternative mechanisms. MTI (Figure 3B) and MTII
(Figure 3C) mRNAs were also markedly induced by zinc
in MTF-1
+/+, Hepa-1 and Nmuli cells, conﬁrming the
efﬁcacy of zinc treatment.
Liver receptor homolog-1 (LRH-1) is a known SHP
activator (31). Further analysis of the SHP promoter
showed that when co-transfected with a SHP promoter
luciferase reporter, MTF-1 not only inhibited the basal
SHP promoter activity (Figure 3D, left), but also re-
pressed LRH-1 transactivation (Figure 3D, right).
Next, Flag-MTF-1 was stably expressed in MTF-1
 / 
MEF cells (designated as M42) for ChIP analysis using an
anti-Flag antibody. A direct association of MTF-1 with
putative metal-response elements in the SHP promoter
(sMRE) was observed (Figure 3E), but the association
was not affected by zinc treatment. In addition, the
levels of endogenous SHP mRNA and protein were
reduced dose-dependently by ectopic expression of
MTF-1 (Figure 3F), demonstrating a direct inhibition of
MTF-1 on SHP expression. GST pull down assays did
not identify physical interactions between SHP and
MTF-1 (data not shown). Overall, the data presented in
Figure 2. SHP inhibition of MTF-1 expression. (A) Semi-quantitative PCR analysis of SHP (45  cycles), MTF-1 (35  cycles) and Dnmt1 (28 
cycles) expression in Nmuli and Hepa-1 cells (left), and in NIH3T3 cells with SHP over-expression (right). (B) qPCR analysis of hepatic MTF-1
mRNA expression in wt and sko, nc and stg mice at 2 and 12 months of age. *P<0.01 versus corresponding control. (C) qPCR analysis of hepatic
MTI and MTII mRNA in wt and sko mice at 2 months of age. *P<0.01 versus corresponding control. (D) qPCR analysis of SHP and MTF-1
mRNA in Hepa-1 cells that over-expressed SHP from an expression vector. *P<0.01 versus control ( ) group without SHP expression. (B–D)
Statistical results represent mean±SD of triplicate assays. (E) WB of MTF-1 and SHP protein in Hepa-1 cells that were over-expressing Flag-SHP
from an expression vector. The endogenous MTF-1 protein was detected using an anti-MTF-1 antibody and the over-expressed SHP protein was
detected using an anti-Flag antibody.
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between SHP and MTF-1.
Zinc-induced Dnmt1 transcription requires MTF-1
We tested the effect of zinc on the expression of MTF-1,
SHP and Dnmt1 in MTF-1
+/+ and MTF-1
 /  MEF cells.
Zinc (Zn) exposure resulted in a marked induction of
MTF-1 mRNA in MTF-1
+/+ MEFs, which was accom-
panied by a decreased SHP expression and increased
Dnmt1 expression (Figure 4A, left). Zn treatment in
MTF-1 deﬁcient (MTF-1
 / ) MEFs induced SHP expres-
sion, which corresponded with the attenuated expression
of Dnmt1 in response to Zn (Figure 4A, right). SHP
mRNA was induced by zinc in MTF-1
 /  MEFs, suggest-
ing an alternative mechanism that activates SHP in
the absence of MTF-1. The increased expression of
SHP may be responsible for the inhibition of Dnmt1
expression.
Dnmt1 protein was elevated by zinc treatment in
MTF-1
+/+ cells compared to untreated cells (Figure 4B).
Surprisingly, Dnmt1 protein showed a signiﬁcant eleva-
tion in basal expression in MTF-1
 /  cells without zinc,
which was reduced by zinc exposure. This result correlated
with the lower SHP levels in MTF-1
 /  MEFs without
zinc and the up-regulation of SHP by zinc (Figures 3A
and 4A).
To conﬁrm if the induction of MTF-1 by zinc is directly
associated with the activation of the Dnmt1 promoter,
MEFs were transfected with the Dnmt1 promoter in the
absence or presence of zinc. The luciferase activity driven
by the Dnmt1 promoter was induced by zinc treatment
in MTF-1
+/+ (Figure 4C, left), consistent with the induc-
tion of MTF-1 expression by zinc in MTF-1
+/+ cells
Figure 3. Zinc inhibition of SHP transcription requires MTF-1. (A) qPCR analysis of MTF-1 and SHP mRNA in Nmuli cells (left), or in MTF-1
+/+
and MTF-1
 /  MEF cells (right), without ( Zn) or with (+Zn, 100mM ZnSO4) treatment for 6hr. *P<0.01,+Zn group versus  Zn group. (B and
C) qPCR analysis of MTI and MTII mRNA in MTF-1
+/+ MEFs, MTF-1
 /  MEFs, Hepa-1 and Nmuli cells, without ( Zn) or with (+Zn, 100mM
ZnSO4) treatment for 6hr. *P<0.01, +Zn group versus  Zn group. (D) Transient transfection assays in Hela cells to determine the activity of the
mSHP promoter luciferase (Luc) reporter in the absence or presence of the expression plasmid for MTF-1 (200ng), without (left) or with LRH-1
(30ng) co-transfection (right). *P<0.01 versus control ( ) group.
¥P<0.01 versus LRH-1 alone. (A–D) Statistical results represent mean±SD of
triplicate assays. (E) Left: diagram showing putative MTF-1 binding sites (MREs) in the SHP promoter. Small letters indicate base pair mismatch
from a consensus MRE. Right: ChIP assays to determine the physical association of MTF-1 with the SHP promoter in M42 cells in the without or
with 100mM ZnSO4 treatment for 6hr. M42 cells were generated by stably re-expressing a Flag-MTF-1 in the MTF-1
 /  MEF cells. (F) Left: qPCR
analysis of MTF-1 and SHP mRNA in Huh7 cells that were overexpressed with a MTF-1 plasmid. Right: WB of MTF-1 and SHP protein in Huh7
cells that were overexpressed with a MTF-1 plasmid. *P<0.01 versus control ( ) group.
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observed in MTF-1
 /  cells without zinc, which was
decreased by zinc. The result was consistent with the al-
terations of Dnmt1 protein (Figure 4B) and SHP mRNA
(Figure 3A, right) in MTF-1
 /  cells. Similar activation of
the Dnmt1 promoter by zinc treatment was observed in
HEK293 cells that have endogenous MTF-1 (Figure 4C,
right).
Several potential binding motifs for MTF-1 (MRE)
were identiﬁed in the Dnmt1 promoter (26) (Figure 4D,
left), suggesting that MTF-1 may be capable of inducing
the transcription of Dnmt1. An association of MTF-1
with the endogenous Dnmt1 promoter was observed
using P1 primers covering three putative MREs in M42
cells that expressed MTF-1, but not in MTF-1
 /  cells
(Figure 4D, top right), and this association was
enhanced by zinc (Figure 4D, bottom right). In addition,
both Dnmt1 mRNA and protein were markedly increased
in M42 cells compared with the wt cells (Figure 4E). The
data suggest that zinc induces Dnmt1 expression by
increasing MTF-1 expression as well as its recruitment
to the Dnmt1 promoter, which in turn activates Dnmt1
gene transcription.
SHP antagonizes zinc-mediated activation of Dnmt1
Activation of a transfected Dnmt1 promoter-luciferase
reporter by zinc was decreased by SHP over-expression
in MTF-1
+/+ and M42 cells (Figure 5A). Basal Dnmt1
promoter activity was somewhat lower in M42. In
MTF-1
 /  cells, zinc treatment decreased Dnmt1-luc
activity which was not further decreased by SHP
over-expression. Furthermore, induction of MTF-1 and
Dnmt1 mRNAs by zinc was repressed by over-expression
of SHP (Figure 5B). In Hepa-1 (mouse HCC) and Huh7
(human HCC) cells, zinc also induced MTF-1 and Dnmt1
mRNAs whereas it reduced SHP mRNA (Figure 5C).
We next used ChIP assays to examine histone modiﬁ-
cations in the Dnmt1 promoter in cells treated with zinc
and over-expressing SHP. Zinc treatment markedly
increased active histone marks (H3Ac, H4Ac and
H3K4Me2) whereas it decreased the inactive histone
mark (H3K9Me2) in the Dnmt1 promoter (Figure 5D).
Figure 4. Zinc activation of Dnmt1 expression requires MTF-1. (A) qPCR analysis of MTF-1, SHP and Dnmt1 mRNA in MTF-1
+/+ and MTF-1
 / 
MEF cells without ( Zn) or with 100mM ZnSO4 treatment for 6hr (+Zn). *P<0.01, +Zn group versus  Zn group. (B) WB of Dnmt1 protein in
MTF-1
+/+ and MTF-1
 /  MEF cells in the without ( ) or with 100mM ZnSO4 treatment for 6hr (+). (C) Left: Transient transfection assays in
MTF-1
+/+ and MTF-1
 /  MEF cells to determine the activation of Dnmt1 promoter-luciferase reporter (Luc) in response to zinc treatment. Right:
Transient transfection assays of the Dnmt1 promoter-luciferase (Luc) reporter in HEK293 cells treated with zinc. Cells were cultured in medium
containing 100mM ZnSO4 for 6hr. *P<0.01, +Zn group versus  Zn group;
§P<0.01,  Zn group in MTF-1
 /  versus  Zn group in MTF-1
+/+
cells;
yP<0.01, +Zn group versus  Zn group in MTF-1
 /  cells. (A and C) Statistical results represent mean±SD of triplicate assays. (D) Left:
diagram showing putative MREs in the Dnmt1 promoter and the location of primers used for ChIP assays. Middle: ChIP assays to monitor the
association of MTF-1 to the endogenous Dnmt1 promoter in MTF-1
 /  and M42 cells in the absence of zinc (upper panel), or in M42 cells treated
with 100mM ZnSO4 for 6hr (lower panel). Right: Quantiﬁcation of the binding signals in ChIP assays. (E) Left: qPCR analysis of MTF-1 and
Dnmt1 mRNA in MEF cells (WT and M42). Right: WB of MTF-1 and Dnmt1 protein in MEF cells (WT and M42).
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of SHP over-expression. These histone modiﬁcations of
the Dnmt1 promoter by SHP correlate with Dnmt1 ex-
pression regulation by SHP. Thus, zinc and SHP counter-
act each others regulation of Dnmt1 promoter activity by
rapidly modulating local chromatin conﬁguration. SHP
did not decrease recruitment of MTF-1 to the Dnmt1
promoter (Figure 5E), it is postulated that MTF-1
utilizes a zinc dependent mechanism to facilitate its
binding to the Dnmt1 promoter and SHP employs a
distinct mechanism not by direct interaction but by in-
hibiting the expression of MTF-1.
SHP expression inversely correlates with DNMT1
expression in human HCC
Our early studies reported decreased SHP mRNA due to
promoter hypermethylation in human HCC specimens
(19). Quantiﬁcation of DNMT1 mRNA levels in 14
matched HCC specimens and paired non-neoplastic liver
tissues (surrounding tissues) revealed elevated DNMT1
mRNA in a majority of these HCC (8/14) (Figure 6A).
Increased DNMT1 mRNA negatively correlated with
decreased SHP mRNA in HCC specimens (Figure 6B),
consistent with a regulatory link between SHP and
DNMT1 expression in HCC.
DISCUSSION
DNA methylation is an epigenetic mark critical for
regulating the chromatin structure and gene transcription.
DNA methylation is mainly catalyzed by three DNA
methyltransferases (Dnmts) encoded by Dnmt1, Dnmt3a
and Dnmt3b. Dnmt1, the maintenance DNA methyltrans-
ferase and a major Dnmt in adult cells, plays an important
role in cancer progression associated with epigenetic
Figure 5. SHP inhibition of MTF-1-dependent induction of Dnmt1. (A) Transient transfection assays of the Dnmt1 promoter-luciferase (Luc)
reporter in MEF (MTF-1
+/+, MTF-1
 /  and M42) cells without ( Zn) or with 100mM ZnSO4 treatment for 6hr (+Zn) and in the absence ( )
or presence (+) of SHP over-expression. *P<0.01,+Zn group versus  Zn group without SHP;
¥P<0.01,+Zn with SHP versus+Zn without SHP;
§P<0.01,  Zn group in MTF-1
 /  versus  Zn group in MTF-1
+/+ cells;
yP<0.01, +Zn group versus  Zn group in MTF-1
 /  cells. (B) qPCR
analysis of MTF-1 and Dnmt1 mRNA in MTF-1
+/+ MEF cells without ( Zn) or with 100mM ZnSO4 treatment for 6hr (+Zn) and without ( )o r
with SHP over-expression (+). *P<0.01,+Zn group versus  Zn group without SHP;
¥P<0.01,+Zn with SHP versus+Zn without SHP. (C) qPCR
analysis of MTF-1, SHP and Dnmt1 mRNA in Hepa-1 and Huh7 cells without ( Zn) or with 100mM ZnSO4 treatment for 6hr (+Zn). *P<0.01,
+Zn group versus  Zn group. (A–D) Statistical results represent mean±SD of triplicate assays. (D) ChIP assays of histone modiﬁcations in the
Dnmt1 promoter after zinc treatment and SHP over-expression. MEF cells were cultured in medium with (+Zn) or without ( Zn) 100mM ZnSO4 for
6hr. ChIP PCR products were ampliﬁed from input-positive controls, IgG-negative controls and antibody immunoprecipitates. Histograms show
antibody/input ratios of PCR products quantiﬁed using qPCR, expressed as Relative (Rel) enrichment. The P1 primers covering the three MREs (see
Figure 4D) were used for ChIP assays. Error bars represent SD from three independent measurements. *P<0.01 versus  Zn group;
¥P<0.01 versus
+Zn group. (E) ChIP assays to determine the effect of SHP expression on the recruitment of MTF-1 to the Dnmt1 promoter. M42 cells were
transfected with or without GFP-SHP plasmid for 36hr and treated with 100mM ZnSO4 for 6hr. The chromatin was immunoprecipitated using
anti-GFP or anti-Flag antibodies. PCR was used to determine the association of SHP and MTF-1 to the endogenous Dnmt1 promoter by using P1
and P2 primers.
4856 Nucleic Acids Research, 2012,Vol.40, No. 11silencing of tumor suppressor genes. Previous work has
shown that the mouse Dnmt1 promoter is independently
activated by Sp1/Sp3 (25) and E2F (26,41), and the
human DNMT1 by signal transducer and activator of
transcription-3 (STAT3) (28) transcription factors.
Dnmt1 expression can also be modulated by Rb (41),
AUF1 (42), BRCA1 (43) and small non-coding
microRNAs miR-152 (44,45). In addition to its expression
regulation, Dnmt1 protein stability is controlled by SET7
(46) and LSD1 (47), and its enzymatic activity is mediated
by G9a (48), EZH2 (49), PML-RAR (50) and hNaa10p
(51). A recent study demonstrated that p53 is a negative
regulator of the Dnmt1 promoter activity (52). However,
the mechanism of Dnmt1 overexpression in cancers
remains largely unknown. The results in this study
identiﬁed a zinc-mediated activation of Dnmt1 that is
modulated by MTF-1 and SHP crosstalk.
An important ﬁnding of this study is our establishment
of a regulatory link between zinc/MTF-1 and Dnmt1 in
HCC. Although there is no report investigating the
speciﬁc function of MTF-1 in the development of liver
cancer, a recent study showed that MTF-1 protein levels
were signiﬁcantly elevated in breast, lung and cervical car-
cinomas (53), suggesting a role for MTF-1 in human
tumor development and growth. MTF-1 was also
proposed as a candidate lymphoma susceptibility gene
(54), and loss of MTF-1 resulted in delayed tumor
growth associated with increased matrix collagen
deposition and reductions in vasculature density (55).
Both tissue hypoxia and oxidative stress are well docu-
mented to be common features of most solid tumors
(56). MTF-1 has been associated with hypoxic-induced
placenta growth factor (PIGF) expression, an angiogenic
factor expressed in many tumors (57). Up-regulation of
MTF-1 and PIGF occurred in human intrahepatic
cholangiocarcinoma due to loss of liver–intestine
cadherin, which contributed to tumor differentiation and
vascular invasion, and thus poor prognosis (58).
Interestingly, we found that the induction of Dnmt1 by
MTF-1 requires the presence of zinc. Zinc not only in-
creases MTF-1 expression, as seen by other studies
(59,60), but more importantly, it also enhances the recruit-
ment of MTF-1 to the Dnmt1 promoter and causes tran-
scriptionally active conﬁguration of the local chromatin.
It should be noted that, in the 14 HCC specimens that
we analyzed (Figure 6), the expression of MTF-1 was
not signiﬁcantly altered, and no strong positive correlation
between MTF-1 and DNMT1 mRNA was observed (data
not shown). This suggests that the disrupted intracellular
zinc homeostasis, but not merely changes of MTF-1
mRNA, may be critical in promoting MTF-1-mediated
activation of Dnmt1. Although it remains to be
determined how zinc metabolism is altered during HCC
growth, MTF-1 may play a role by activating Dnmt1
under aberrant metal conditions. Up-regulated Dnmt1
may further silence other tumor suppressors and stimulate
Figure 6. Inverse correlation between DNMT1 and SHP mRNAs in human HCC. (A) qPCR analysis of DNMT1 and SHP mRNAs in 14 pairs of
human HCC specimens (HCC) and their corresponding normal surrounding tissues (NT). The expression of DNMT1 and SHP in HCC was
normalized to NT and the results were expressed as log 2. (B) Correlation between DNMT1 and SHP mRNA abundance in human HCC.
Nucleic Acids Research, 2012,Vol.40, No. 11 4857HCC progression. It would be interesting to determine
in future studies whether hypoxia or oxidative stress con-
tribute to Dnmt1 expression regulation by MTF-1. In this
regard, MTF-1 could be a potential therapeutic target that
offers the opportunity to manipulate metal or redox
homeostasis in tumor cells.
One intriguing observation is the cross-inhibition
between SHP and MTF-1. SHP directly represses
MTF-1 expression at the transcriptional level. Conversely,
induction of MTF-1 by zinc inhibits SHP expression by
binding to the SHP promoter and repressing the basal, as
well as LRH-1-induced SHP promoter activity.
Surprisingly, the basal level of SHP is decreased in
MTF-1-deﬁcient MEFs, which is induced by zinc. On
the other hand, the induction of MTF-1 target gene
MTI, as well as Dnmt1, is observed in MTF-1
 /  cells,
which is repressed by zinc. The changes in SHP may be
responsible for the alterations of Dnmt1. It is postulated
that MTF-1 may play a predominant role to control a
zinc-dependent activation of Dnmt1 through inhibition
of SHP. In the absence of MTF-1, zinc may turn on
other zinc responsive genes that function as SHP activa-
tors, resulting in the elevation of SHP and reduction of
Dnmt1.
Recently we showed that SHP also inhibits Dnmt1
promoter transactivation by ERRg in several cancer
cells (29). The effect of SHP is through a direct protein–
protein interaction with ERRg to convert the local
chromatin structure of the Dnmt1 promoter from a tran-
scriptionally active mode to an inactive mode. Because
SHP does not interact with the MTF-1 protein directly,
SHP appears to repress Dnmt1 through decreasing
MTF-1 expression. The induction of MTF-1 by zinc
may activate Dnmt1 by repressing SHP, which represents
a feed-forward inhibitory mechanism between SHP and
MTF-1 that controls Dnmt1 expression. Thus, SHP
modulates the expression of Dnmt1 by at least two
distinct mechanisms (Figure 7).
In conclusion, we identiﬁed a second pathway through
which SHP represses Dnmt1. SHP inhibition of Dnmt1
may affect global DNA methylation and alter methylation
levels of tumor suppressors. Targeting SHP may prove a
useful approach to demethylate and reactivate the silenced
tumor suppressors to slow the progression of HCC.
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